Reviva Pharmaceuticals Prices $9 Million Public Offering
MT Newswires Live
Sep 19
Reviva Pharmaceuticals (RVPH) said Thursday it has priced a public offering of 27 million shares together with accompanying series E warrants to purchase up to 27 million and series F warrants to purchase up to 27 million shares $0.335 per share and accompanying warrants.
Gross proceeds are estimated to be $9 million and the offering is expected to close Monday, the company said.
The company plans to use net proceeds from the offering to fund research and development and for general corporate purposes.
Shares of the company fell more than 27% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.